Who are olmesartan medoxomil and a diuretic's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olmesartan-medoxomil-and-a-diuretic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

olmesartan medoxomil and a diuretic — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

olmesartan medoxomil and a diuretic (olmesartan medoxomil and a diuretic) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB) + diuretic combination. Area: Cardiovascular.

marketed Angiotensin II receptor blocker (ARB) + diuretic combination AT1 receptor (angiotensin II type 1 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

olmesartan medoxomil and a diuretic (olmesartan medoxomil and a diuretic) — Daiichi Sankyo Co., Ltd.. Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while the diuretic component enhances sodium and water excretion to further reduce fluid volume and blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
olmesartan medoxomil and a diuretic TARGET	olmesartan medoxomil and a diuretic	Daiichi Sankyo Co., Ltd.	marketed	Angiotensin II receptor blocker (ARB) + diuretic combination	AT1 receptor (angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) + diuretic combination class)

Daiichi Sankyo Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). olmesartan medoxomil and a diuretic — Competitive Intelligence Brief. https://druglandscape.com/ci/olmesartan-medoxomil-and-a-diuretic. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab